• 1
    Bayley AC. Aggressive Kaposi's sarcoma in Zambia, 1983. Lancet 1984; 1: 13181320.
  • 2
    Wabinga HR, Parkin DM, Wabwire-Mangen F, et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 2000; 82: 15851592.
  • 3
    Parkin DM, Ferlay J, Hamdi-Cherif M, et al. Cancer in Africa—Epidemiology and prevention, Chapter 4.6. WHO IARC Scientific Publications No 153. Lyon: IARC Press; 2003. pp 286291.
  • 4
    Friedman-Kien AE, Laubenstein LJ, Rubinstein P, et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96: 693700.
  • 5
    Bayley AC. Occurrence, clinical behaviour and management of Kaposi's sarcoma in Zambia. Cancer Surv 1991; 10: 5371.
  • 6
    Sinfield RL, Molyneux EM, Banda K, et al. Spectrum and presentation of pediatric malignancies in the HIV era: Experience from Blantyre, Malawi, 1998–2003. Pediatr Blood Cancer 2007; 48: 515520.
  • 7
    Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468476.
  • 8
    Davidson A, Hendricks M, Geel J, et al. Malignancy in HIV positive South African children. Pediatr Blood Cancer 2009; 53: 719.
  • 9
    Mosam A, Aboobaker J, Shaik F. Kaposi's sarcoma in sub-Saharan Africa: A current perspective. Curr Opin Infect Dis 2010; 23: 119123.
  • 10
    Cairncross LL, Davidson A, Millar AJ, et al. Kaposi sarcoma in children with HIV: A clinical series from Red Cross Children's Hospital. J Pediatr Surg 2009; 44: 373376.
  • 11
    Theron S, Andronikou S, George R, et al. Non-infective pulmonary disease in HIV-positive children. Pediatr Radiol 2009; 39: 555564.
  • 12
    Gantt S, Kakuru A, Wald A, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer 2010; 54: 670674.
  • 13
    Rezza G, Dorrucci M, Serraino D, et al. Incidence of Kaposi's sarcoma and HHV 8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study. AIDS 2000; 14: 16471653.
  • 14
    Pantonowitz L, Dezube BJ. Kaposi Sarcoma in unusual locations. BMC Cancer 2008; 8: 190. DOI: 10.1186/1471-2407-8-190
  • 15
    Wright CA., Fine-needle aspiration biopsy of lymph nodes. Continuing Medical Education 2012; vol 30; number 2. Accessed August 27, 2012.
  • 16
    Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7: 12011207.
  • 17
    Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15: 30853092.
  • 18
    Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's Sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—The Italian Cooperative Group on AIDS and Tumors and the Italian cohort of patients naive from antiretrovirals. J Clin Oncol 2003; 21: 28762882.
  • 19
    Arora RS, Eden T. The problem of treatment abandonment in children from developing countries with cancer. PBC 2007; 49: 941946.
  • 20
    Israel T, Chirambo C, Caron H, et al. The guardians persperctive on paediatric cancer treatment in Malawi and factors affecting adherence. PBC 2008; 51: 639642.
  • 21
    Sitaresmi MN, Mostert S, Schook RM, et al. Treatment refusal and abandonment in childhood acute lymphoblastic leukemia in Indonesia: An analysis of causes and consequences. Psychooncology 2010; 19: 361367.
  • 22
    Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev 2003; CD003256.
  • 23
    Stefan DC, Stones DK, Wainwright L, et al. Kaposi sarcoma in South African children. Pediatr Blood Cancer 2011; 56: 392396.
  • 24
    Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: A prospective study. AIDS 2008; 22: 601610.
  • 25
    Letang E, Almeida JM, Miro JM, et al. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: A prospective study. J Acquir Immune Defic Syndr 2010; 53: 589597.
  • 26
    Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23: 52245228.
  • 27
    Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS related Kaposi's sarcoma. AIDS 2009; 23: 17011706.
  • 28
    D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 40824085.
  • 29
    Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998; 9: 751755.
  • 30
    Cheung TW, Remick SC, Azarnia N, et al. AIDS-related Kaposi's sarcoma: A phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin Cancer Res 1999; 5: 34323437.
  • 31
    Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999; 17: 18761883.
  • 32
    Rubegni P, Sbano P, De AG, et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology 2007; 215: 240244.
  • 33
    Hodgson T, Kondowe W, Molyneux EM, et al. Proceedings paper 10th international congress on oral cancer pp140. Crete Greece 19.04.20045-24.4.2005.
  • 34
    Sgadari C, Monini P, Barillari G, et al. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4: 537547.
  • 35
    Kumar M, Sharma U, Singh C, et al. Thalidomide: Chemistry, therapeutic potential and oxidative stress indiced tetragenicity. Curr Top Med Chem 2012; 12: 14361465.
  • 36
    Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009; 23: 17011706.
  • 37
    Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV associated malignancies 2008. HIV Med 2008; 9: 336388.
  • 38
    Nasti G, Errante D, Santarossa S, et al. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Saf 1999; 20: 403425.
  • 39
    Hernandez DE, Perez JR. Advanced epidemic Kaposi's sarcoma: Treatment with bleomycin or combination of doxorubicin, bleomycin, and vincristine. Int J Dermatol 1996; 35: 831833.
  • 40
    Gill PS, Rarick M, McCutchan JA, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am J Med 1991; 90: 427433.
  • 41
    Gill PS, Weinz J, Scadden DT, et al. Randomised phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 23532364.
  • 42
    Francis H, Bates MJ, Kalilani L. A prospective study assessing tumour response, survival and palliative care outcomes in patients with HIV-related Kaposi's sarcoma at the Queen Elizabeth Central Hospital, Blantyre Malawi. AIDS Res Treat 2012; 2012: 312564.
  • 43
    Mostellar RD. Simplified calculation of body-surface area. N Eng J Med 1987; 317: 1098.
  • 44
    UKCSSG Chemotherapy Standardisation Group 1998. Estimation of Body-Surface Area in Infants and Children.